Altamira Therapeutics Ltd.
Index- P/E- EPS (ttm)-26.93 Insider Own7.10% Shs Outstand1.17M Perf Week4.35%
Market Cap3.45M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.09M Perf Month-45.97%
Income-19.70M PEG- EPS next Q- Inst Own1.90% Short Float / Ratio1.73% / 0.43 Perf Quarter-52.79%
Sales1.40M P/S2.46 EPS this Y3.70% Inst Trans45.40% Short Interest0.02M Perf Half Y-68.52%
Book/sh10.85 P/B0.27 EPS next Y- ROA-87.70% Target Price- Perf Year-88.66%
Cash/sh0.34 P/C8.61 EPS next 5Y- ROE-125.40% 52W Range2.70 - 43.00 Perf YTD-40.62%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-93.30% Beta1.45
Dividend %- Quick Ratio0.20 Sales past 5Y- Gross Margin- 52W Low6.67% ATR0.40
Employees17 Current Ratio0.20 Sales Q/Q- Oper. Margin- RSI (14)29.53 Volatility5.95% 9.46%
OptionableYes Debt/Eq0.62 EPS Q/Q18.70% Profit Margin- Rel Volume0.56 Prev Close2.92
ShortableYes LT Debt/Eq0.00 EarningsNov 30 BMO Payout- Avg Volume43.26K Price2.88
Recom- SMA20-29.28% SMA50-39.67% SMA200-66.45% Volume17,098 Change-1.37%
Feb-07-23 08:47AM
Jan-27-23 08:47AM
Jan-24-23 08:17AM
Jan-10-23 08:47AM
Dec-19-22 08:47AM
08:47AM Loading…
Dec-02-22 08:47AM
Nov-30-22 08:47AM
Nov-22-22 08:47AM
Nov-10-22 08:47AM
Nov-09-22 08:47AM
Nov-08-22 08:47AM
Oct-24-22 08:47AM
Oct-21-22 08:47AM
Oct-13-22 08:47AM
08:47AM Loading…
Oct-03-22 08:47AM
Sep-27-22 08:47AM
Sep-13-22 08:47AM
Sep-08-22 08:57AM
Aug-30-22 09:24AM
Aug-03-22 12:15PM
Aug-01-22 08:47AM
Jul-28-22 08:47AM
Jul-25-22 08:47AM
Jul-19-22 08:47AM
Jul-12-22 08:47AM
Jun-29-22 07:30AM
Jun-27-22 08:30AM
Jun-23-22 08:47AM
08:47AM Loading…
Jun-13-22 08:47AM
Jun-09-22 05:25PM
Jun-08-22 08:47AM
May-31-22 08:47AM
May-23-22 08:47AM
May-20-22 09:00AM
May-19-22 09:00AM
May-18-22 08:47AM
May-05-22 08:47AM
Apr-19-22 09:00AM
Apr-12-22 07:30AM
Apr-11-22 08:47AM
Apr-04-22 08:47AM
Mar-15-22 09:00AM
Mar-11-22 09:00AM
Mar-09-22 09:00AM
Mar-04-22 09:15AM
Feb-14-22 09:00AM
Feb-09-22 09:00AM
Feb-07-22 09:00AM
Feb-04-22 09:25AM
Jan-21-22 09:00AM
Jan-13-22 09:00AM
Jan-05-22 09:00AM
Dec-29-21 09:15AM
Dec-16-21 09:00AM
Dec-01-21 09:00AM
Nov-15-21 09:00AM
Nov-12-21 09:00AM
Oct-25-21 09:00AM
Oct-14-21 08:00AM
Oct-06-21 08:00AM
Oct-01-21 08:04PM
Sep-27-21 07:45AM
Sep-21-21 08:00AM
Sep-09-21 08:30AM
Sep-08-21 08:30AM
Aug-06-21 09:00AM
Aug-03-21 09:00AM
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.